Manipal Health IPO: Can Aggressive Valuation Stall Growth Amid Margin Pressure?

Manipal Health IPO: Can Aggressive Valuation Stall Growth Amid Margin Pressure?​

Manipal Health Enterprises' upcoming Initial Public Offering (IPO) presents a complex picture for investors. The healthcare provider plans to raise ₹8,000 crore through a fresh issue for debt repayment and corporate purposes, alongside an offer for sale of ₹1,275 crore. This move is set to see the promoter group's stake reduce from 81.4% to 72.1%.

Financial Performance and Operational Snapshot​

Manipal Health has demonstrated strong past revenue growth. Revenue from operations grew by 29.4% annually, reaching ₹10,335.8 crore between FY24 and FY26. Net profit also rose by 31.1% to ₹916.5 crore over the same period.

Operationally, the company is a significant entity in healthcare. As of March 31, 2026, Manipal Health operated 49 hospitals with 13,037 licensed beds and 21 clinics. It stands as the largest pan-India multispecialty hospital network by bed capacity and the second largest chain by number of hospitals, following Apollo Hospitals, according to a Crisil report.

Key Operational Metrics and Concerns​

Despite revenue growth, operational efficiency shows areas needing attention. The company's occupancy rate in FY26 stood at 64.5%, which is lower than the 67-76% range reported by its peers. Furthermore, their average length of stay was 2.8 days, compared to the peer average of 3.2 to 4.2 days.

Financially, while one-year revenue growth stood at 25.4%, EBITDA rose 22.1%. However, net profit declined 15.3% in FY26. The EBITDA margin dropped to 25.6% in FY26 from 27.5% in FY24, indicating notable margin pressure.

Market Positioning and Valuation Risks​

The company's operations are heavily focused on specialized care. Over 64% of its revenue is derived from CONGO-R specialties (cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics, and renal sciences). This focus provides a concentrated operational strength.

Valuation presents a significant concern for prospective investors. When considering the post-IPO equity and net profit for FY26, Manipal Health is demanding a Price-to-Earnings (P/E) multiple of 85. This valuation is notably higher than that of its peers, which are trading in the range of 62 to 68.

Investor Viewpoint: What Does This Mean?​

The IPO requires careful consideration given these varied factors. The reported margin pressure and the aggressive valuation make it necessary for investors to wait for clarity post-listing. The company's significant geographic concentration, with over 46% of revenue coming from Karnataka, adds another layer of risk assessment. Investors are therefore advised to balance the strong foundational growth with the existing profitability challenges and premium pricing demanded by the listing.